← Back to All US Stocks

Qiagen N.v. (QGEN) Fundamental Analysis & AI Grade 2026

QGEN NYSE Biological Products, (No Diagnostic Substances) P7 CIK: 0001015820
Recently Updated • Analysis: May 28, 2026 • SEC Data: 2026-05-28

Qiagen N.v. (QGEN) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

QGEN Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

QGEN vs Healthcare Sector: How Qiagen N.v. Compares

How Qiagen N.v. compares to Healthcare sector averages

Net Margin
QGEN 0.0%
vs
Sector Avg 12.0%
QGEN Sector
ROE
QGEN 0.0%
vs
Sector Avg 15.0%
QGEN Sector
Current Ratio
QGEN 0.0x
vs
Sector Avg 2.0x
QGEN Sector
Debt/Equity
QGEN 0.0x
vs
Sector Avg 0.6x
QGEN Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Qiagen N.v. Stock Overvalued? QGEN Valuation Analysis 2026

Based on fundamental analysis, Qiagen N.v. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Qiagen N.v. Balance Sheet: QGEN Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

QGEN Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

QGEN SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Qiagen N.v. (CIK: 0001015820)

📋 Recent SEC Filings

Date Form Document Action
Nov 8, 2024 SC 13G SEC13G_Filing.htm View →
Nov 7, 2024 SC 13G nl0015001wm6_110724.txt View →
Oct 21, 2024 SC 13G nl0015001wm6_102124.txt View →
Jan 26, 2022 SC 13G nl0012169213_012522.txt View →
Aug 3, 2020 SC 13D p20-1426sc13d.htm View →

Frequently Asked Questions about QGEN

What is the AI rating for QGEN?

Qiagen N.v. (QGEN) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.

What are QGEN's key strengths?

Claude: Analysis in progress.

What are the risks of investing in QGEN?

Claude: Analysis in progress.

What is QGEN's revenue and growth?

Qiagen N.v. reported revenue of N/A.

Does QGEN pay dividends?

Qiagen N.v. does not currently pay dividends.

Where can I find QGEN SEC filings?

Official SEC filings for Qiagen N.v. (CIK: 0001015820) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is QGEN's EPS?

Qiagen N.v. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is QGEN's fundamental grade?

Based on our AI fundamental analysis in May 2026, Qiagen N.v. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is QGEN stock overvalued or undervalued?

Valuation metrics for QGEN: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is QGEN's AI grade for 2026?

Our dual AI analysis gives Qiagen N.v. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is QGEN's free cash flow?

Qiagen N.v.'s operating cash flow is N/A, with capital expenditures of N/A.

How does QGEN compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 28, 2026 | Data as of: 2026-05-28 | Powered by Claude AI